Spots Global Cancer Trial Database for recurrent neuroblastoma
Every month we try and update this database with for recurrent neuroblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | NCT02075177 | Recurrent Neuro... Neuroblastoma | Fenretinide Lym... Ketoconazole | - | South Plains Oncology Consortium | |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT00939770 | Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur... | Crizotinib Laboratory Biom... Pharmacological... Questionnaire A... | 1 Year - 21 Years | Children's Oncology Group | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions | NCT00436696 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... | Laboratory Biom... | - | Children's Oncology Group | |
| Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT00450827 | Neuroblastoma | bevacizumab filgrastim autologous hema... iodine I 131 mo... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | NCT00659984 | Neuroblastoma | UltratraceTM Io... UltratraceTM Io... | 1 Year - 30 Years | Molecular Insight Pharmaceuticals, Inc. | |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | NCT03526250 | Advanced Malign... Recurrent Child... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... | Laboratory Biom... Palbociclib Pharmacological... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | NCT01048892 | Adrenocortical ... Gastrointestina... Kidney Cancer Neuroblastoma Retinoblastoma Sarcoma | Seneca Valley v... cyclophosphamid... laboratory biom... pharmacological... | 3 Years - 21 Years | Children's Oncology Group | |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | NCT00567567 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma | NCT00006102 | Brain and Centr... Lymphoma Neuroblastoma Retinoblastoma Sarcoma Unspecified Chi... | becatecarin | - 21 Years | National Cancer Institute (NCI) | |
| Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma | NCT00054405 | Recurrent Neuro... | recombinant int... aldesleukin | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT00082758 | Neuroblastoma | hu14.18-Interle... | - 21 Years | Children's Oncology Group | |
| Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | NCT00410631 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma | NCT00037011 | Neuroblastoma | beta-glucan monoclonal anti... | - 49 Years | Memorial Sloan Kettering Cancer Center | |
| 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma | NCT00293319 | Neuroblastoma | filgrastim iobenguane I 13... | 1 Year - | University of California, San Francisco | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | NCT00003461 | Brain and Centr... Metastatic Canc... Neuroblastoma | surgical proced... astatine At 211... | 18 Years - | Duke University | |
| N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | NCT00093353 | Diarrhea Drug/Agent Toxi... Neuroblastoma | cefixime irinotecan hydr... temozolomide | 1 Year - 30 Years | Children's Hospital Los Angeles | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | NCT00885326 | Neuroblastoma | Bevacizumab cyclophosphamid... zoledronic acid | - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | NCT00107289 | Neuroblastoma Pheochromocytom... | iobenguane I 13... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | NCT03698994 | Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor | Pharmacokinetic... Ulixertinib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma | NCT01358617 | Disseminated Ne... Localized Resec... Localized Unres... Recurrent Neuro... Stage 4S Neurob... | diagnostic labo... | - | Children's Oncology Group | |
| Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | NCT00450307 | Neuroblastoma | monoclonal anti... sargramostim | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma | NCT03057626 | Recurrent Neuro... Stage 2A Neurob... Stage 2B Neurob... Stage 3 Neurobl... Stage 4 Neurobl... Stage 4S Neurob... | Cytology Specim... Laboratory Biom... Quality-of-Life... | 5 Years - 50 Years | Children's Oncology Group | |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT00026312 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Aldesleukin Dinutuximab Isotretinoin Laboratory Biom... Pharmacological... Quality-of-Life... Sargramostim | - 30 Years | National Cancer Institute (NCI) | |
| Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma | NCT00392340 | Neuroblastoma | filgrastim doxorubicin hyd... topotecan hydro... vincristine sul... | 1 Year - 20 Years | National Cancer Institute (NCI) | |
| Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma | NCT00053326 | Recurrent Neuro... | fenretinide pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | NCT00253435 | Neuroblastoma | Filgrastim Carboplatin Etoposide Melphalan Peripheral bloo... 131I-MIBG Radiation thera... | 1 Year - 29 Years | Children's Hospital Los Angeles | |
| Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | NCT02452554 | Pleuropulmonary... Recurrent Malig... Recurrent Neuro... Recurrent Rhabd... Recurrent Synov... Wilms Tumor | Laboratory Biom... Lorvotuzumab Me... Pharmacological... | 12 Months - 30 Years | Children's Oncology Group | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | NCT00003461 | Brain and Centr... Metastatic Canc... Neuroblastoma | surgical proced... astatine At 211... | 18 Years - | Duke University | |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | NCT00084422 | Neuroblastoma | lestaurtinib | 1 Day - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | NCT00939965 | Neuroblastoma | isotretinoin DNA analysis polymerase chai... laboratory biom... pharmacological... | - 18 Years | National Cancer Institute (NCI) | |
| N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | NCT00509353 | Neuroblastoma | irinotecan hydr... vincristine sul... iobenguane I 13... | 1 Year - 30 Years | Children's Hospital Los Angeles | |
| Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma | NCT01711554 | Recurrent Neuro... Refractory Neur... | Dinutuximab Isotretinoin Laboratory Biom... Lenalidomide Pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | NCT00089258 | Neuroblastoma | beta-glucan monoclonal anti... sargramostim isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| R(+)XK469 in Treating Patients With Advanced Neuroblastoma | NCT00028522 | Disseminated Ne... Localized Unres... Recurrent Neuro... Regional Neurob... | R(+)XK469 | 5 Years - 20 Years | National Cancer Institute (NCI) | |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT00939770 | Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur... | Crizotinib Laboratory Biom... Pharmacological... Questionnaire A... | 1 Year - 21 Years | Children's Oncology Group | |
| hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT00082758 | Neuroblastoma | hu14.18-Interle... | - 21 Years | Children's Oncology Group | |
| Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma | NCT01208454 | Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Isotretinoin Laboratory Biom... Pharmacological... Vorinostat | - 30 Years | National Cancer Institute (NCI) | |
| N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | NCT00253435 | Neuroblastoma | Filgrastim Carboplatin Etoposide Melphalan Peripheral bloo... 131I-MIBG Radiation thera... | 1 Year - 29 Years | Children's Hospital Los Angeles | |
| Study of DNA in Blood Samples From Patients With Neuroblastoma | NCT00898391 | Disseminated Ne... Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4S Neurob... | laboratory biom... polymerase chai... polyacrylamide ... DNA analysis | - | Children's Oncology Group | |
| N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | NCT00295919 | Neuroblastoma | fenretinide lip... ketoconazole laboratory biom... pharmacological... | 0 Years - 30 Years | Children's Hospital Los Angeles | |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | NCT00084422 | Neuroblastoma | lestaurtinib | 1 Day - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | NCT00070200 | Neuroblastoma | filgrastim cisplatin cyclophosphamid... doxorubicin hyd... etoposide isotretinoin melphalan topotecan hydro... vincristine sul... conventional su... peripheral bloo... radiation thera... | - 30 Years | Children's Oncology Group | |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | NCT04751383 | High Risk Neuro... Recurrent Neuro... Recurrent Osteo... Refractory Neur... Resectable Oste... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Dinutuximab Magnetic Resona... Magrolimab Resection | 2 Years - 35 Years | National Cancer Institute (NCI) | |
| Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | NCT01334515 | Recurrent Neuro... | hu14.18-IL2 fus... isotretinoin sargramostim laboratory biom... | 1 Year - 30 Years | Children's Oncology Group | |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | NCT04284774 | Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ... | Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma | NCT00006480 | Neuroblastoma | aldesleukin therapeutic aut... chemotherapy ganciclovir | 1 Year - 17 Years | Fred Hutchinson Cancer Center | |
| Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma | NCT02075177 | Recurrent Neuro... Neuroblastoma | Fenretinide Lym... Ketoconazole | - | South Plains Oncology Consortium | |
| N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma | NCT00646230 | Neuroblastoma | fenretinide high performanc... pharmacological... | 0 Years - 30 Years | Children's Hospital Los Angeles | |
| Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma | NCT01510600 | Neuroblastoma | DNA analysis polymerase chai... laboratory biom... medical chart r... | - 30 Years | Children's Oncology Group | |
| Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma | NCT00002634 | Neuroblastoma | filgrastim monoclonal anti... cisplatin cyclophosphamid... doxorubicin hyd... etoposide mesna perfosfamide vincristine sul... autologous bone... in vitro-treate... low-LET cobalt-... low-LET photon ... radioisotope th... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma | NCT00392340 | Neuroblastoma | filgrastim doxorubicin hyd... topotecan hydro... vincristine sul... | 1 Year - 20 Years | National Cancer Institute (NCI) | |
| Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | NCT01767194 | Ganglioneurobla... Recurrent Neuro... | Dinutuximab Irinotecan Hydr... Laboratory Biom... Sargramostim Temozolomide Temsirolimus | - | National Cancer Institute (NCI) | |
| Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma | NCT00107289 | Neuroblastoma Pheochromocytom... | iobenguane I 13... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | NCT03213678 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Malignant Gliom... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor | Biospecimen Col... Computed Tomogr... FDG-Positron Em... Magnetic Resona... Samotolisib X-Ray Imaging | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma | NCT00311584 | Neuroblastoma | irinotecan hydr... temozolomide | - 21 Years | Children's Oncology Group | |
| N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | NCT01019850 | Neuroblastoma | Vorinostat 131- I Metaiodo... Peripheral Bloo... Filgrastim | 2 Years - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | NCT04320888 | Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor | Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | NCT00002543 | Brain and Centr... Lymphoma Neuroblastoma Sarcoma Unspecified Chi... | gallium nitrate | - 21 Years | National Cancer Institute (NCI) | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol | NCT01163383 | Neuroblastoma Childhood Metas... | 131 I-Metaiodob... 131 I-MIBG | 1 Year - | Children's Hospital of Philadelphia | |
| N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00005978 | Neuroblastoma | filgrastim carboplatin etoposide melphalan autologous bone... peripheral bloo... iobenguane I 13... radiation thera... | 1 Year - 21 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma | NCT00960739 | Neuroblastoma | Topotecan hydro... Autologous hema... iobenguane I 13... total-body irra... | 1 Year - 20 Years | Centre Oscar Lambret | |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | NCT03698994 | Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor | Pharmacokinetic... Ulixertinib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | NCT00492167 | Neuroblastoma | beta-glucan monoclonal anti... immunohistochem... laboratory biom... | 0 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma | NCT00075634 | Recurrent Neuro... Unspecified Chi... | decitabine doxorubicin hyd... cyclophosphamid... filgrastim pegfilgrastim laboratory biom... pharmacological... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT00082758 | Neuroblastoma | hu14.18-Interle... | - 21 Years | Children's Oncology Group | |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | NCT04500548 | Constitutional ... Hematopoietic a... Lynch Syndrome Recurrent Lymph... Recurrent Malig... Recurrent Neuro... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Neur... Refractory Prim... Xeroderma Pigme... | Biospecimen Col... Ipilimumab Nivolumab | 12 Months - 25 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | NCT01576692 | Neuroblastoma | Humanized anti-... Chemotherapy Cytokines Natural killer ... CliniMACS | - 21 Years | St. Jude Children's Research Hospital | |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | NCT03213691 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... | Laboratory Biom... Selumetinib Selumetinib Sul... | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma | NCT00084422 | Neuroblastoma | lestaurtinib | 1 Day - 30 Years | New Approaches to Neuroblastoma Therapy Consortium | |
| Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | NCT00492167 | Neuroblastoma | beta-glucan monoclonal anti... immunohistochem... laboratory biom... | 0 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | NCT01132547 | Cancer | cyproheptadine ... placebo | 2 Years - 21 Years | University of South Florida | |
| Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | NCT00089258 | Neuroblastoma | beta-glucan monoclonal anti... sargramostim isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | NCT02173093 | Disseminated Ne... Recurrent Neuro... | IL-2 GD2Bi-aATC GM-CSF laboratory eval... | 13 Months - 29 Years | University of Virginia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
